222 related articles for article (PubMed ID: 28399450)
1. Synthesis of new N3-substituted dihydropyrimidine derivatives as L-/T- type calcium channel blockers.
Teleb M; Zhang FX; Farghaly AM; Aboul Wafa OM; Fronczek FR; Zamponi GW; Fahmy H
Eur J Med Chem; 2017 Jul; 134():52-61. PubMed ID: 28399450
[TBL] [Abstract][Full Text] [Related]
2. Synthesis and biological evaluation of novel N3-substituted dihydropyrimidine derivatives as T-type calcium channel blockers and their efficacy as analgesics in mouse models of inflammatory pain.
Teleb M; Zhang FX; Huang J; Gadotti VM; Farghaly AM; AboulWafa OM; Zamponi GW; Fahmy H
Bioorg Med Chem; 2017 Mar; 25(6):1926-1938. PubMed ID: 28233679
[TBL] [Abstract][Full Text] [Related]
3. Binding mechanism investigations guiding the synthesis of novel condensed 1,4-dihydropyridine derivatives with L-/T-type calcium channel blocking activity.
Schaller D; Gündüz MG; Zhang FX; Zamponi GW; Wolber G
Eur J Med Chem; 2018 Jul; 155():1-12. PubMed ID: 29843108
[TBL] [Abstract][Full Text] [Related]
4. Design, synthesis and pharmacological evaluation of some substituted dihydropyrimidines with L-/T-type calcium channel blocking activities.
Teleb M; Rizk OH; Zhang FX; Fronczek FR; Zamponi GW; Fahmy H
Bioorg Chem; 2019 Mar; 83():354-366. PubMed ID: 30408648
[TBL] [Abstract][Full Text] [Related]
5. Synthesis and evaluation of 1,4-dihydropyridine derivatives with calcium channel blocking activity.
Bladen C; Gündüz MG; Şimşek R; Şafak C; Zamponi GW
Pflugers Arch; 2014 Jul; 466(7):1355-63. PubMed ID: 24149495
[TBL] [Abstract][Full Text] [Related]
6. Structural optimization, synthesis and in vitro synergistic anticancer activities of combinations of new N3-substituted dihydropyrimidine calcium channel blockers with cisplatin and etoposide.
El-Wakil MH; Teleb M; Abu-Serie MM; Huang S; Zamponi GW; Fahmy H
Bioorg Chem; 2021 Oct; 115():105262. PubMed ID: 34411980
[TBL] [Abstract][Full Text] [Related]
7. Synthesis of some new C2 substituted dihydropyrimidines and their electrophysiological evaluation as L-/T-type calcium channel blockers.
Teleb M; Rizk OH; Zhang FX; Fronczek FR; Zamponi GW; Fahmy H
Bioorg Chem; 2019 Jul; 88():102915. PubMed ID: 31005784
[TBL] [Abstract][Full Text] [Related]
8. Focusing on C-4 position of Hantzsch 1,4-dihydropyridines: Molecular modifications, enantioseparation, and binding mechanism to L- and T-type calcium channels.
Akman D; Denzinger K; Huang S; Lee JT; Nafie JW; Wolber G; Zamponi GW; Armstrong DW; Gündüz MG
Eur J Med Chem; 2022 Dec; 244():114787. PubMed ID: 36209630
[TBL] [Abstract][Full Text] [Related]
9. Antagonism of L-type Ca2+ channels CaV1.3 and CaV1.2 by 1,4-dihydropyrimidines and 4H-pyrans as dihydropyridine mimics.
Kang S; Cooper G; Dunne SF; Luan CH; James Surmeier D; Silverman RB
Bioorg Med Chem; 2013 Jul; 21(14):4365-73. PubMed ID: 23688558
[TBL] [Abstract][Full Text] [Related]
10. Selective inhibitory action of Biginelli-type dihydropyrimidines on depolarization-induced arterial smooth muscle contraction.
Cernecka H; Veizerova L; Mensikova L; Svetlik J; Krenek P
J Pharm Pharmacol; 2012 May; 64(5):735-41. PubMed ID: 22471370
[TBL] [Abstract][Full Text] [Related]
11. Permanently charged chiral 1,4-dihydropyridines: molecular probes of L-type calcium channels. Synthesis and pharmacological characterization of methyl(omega-trimethylalkylammonium) 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylate iodide, calcium channel antagonists.
Peri R; Padmanabhan S; Rutledge A; Singh S; Triggle DJ
J Med Chem; 2000 Jul; 43(15):2906-14. PubMed ID: 10956198
[TBL] [Abstract][Full Text] [Related]
12. Calcium entry blockers and activators: conformational and structural determinants of dihydropyrimidine calcium channel modulators.
Rovnyak GC; Kimball SD; Beyer B; Cucinotta G; DiMarco JD; Gougoutas J; Hedberg A; Malley M; McCarthy JP; Zhang R
J Med Chem; 1995 Jan; 38(1):119-29. PubMed ID: 7837222
[TBL] [Abstract][Full Text] [Related]
13. Comparative QSAR studies of two series of 1,4-dihydropyridines as slow calcium channel blockers.
Wikel JH; Bemis KG; Kurz K; Denney ML; Main BW; Moore RA; Smith T; Shingleton L; Holland DR
Drug Des Discov; 1994 Jan; 11(1):1-14. PubMed ID: 8068815
[TBL] [Abstract][Full Text] [Related]
14. A novel dihydropyridine with 3-aryl meta-hydroxyl substitution blocks L-type calcium channels in rat cardiomyocytes.
Galvis-Pareja D; Zapata-Torres G; Hidalgo J; Ayala P; Pedrozo Z; Ibarra C; Diaz-Araya G; Hall AR; Vicencio JM; Nuñez-Vergara L; Lavandero S
Toxicol Appl Pharmacol; 2014 Aug; 279(1):53-62. PubMed ID: 24844443
[TBL] [Abstract][Full Text] [Related]
15. Stereochemical requirements for the mineralocorticoid receptor antagonist activity of dihydropyridines.
Arhancet GB; Woodard SS; Dietz JD; Garland DJ; Wagner GM; Iyanar K; Collins JT; Blinn JR; Numann RE; Hu X; Huang HC
J Med Chem; 2010 May; 53(10):4300-4. PubMed ID: 20408553
[TBL] [Abstract][Full Text] [Related]
16. 1,4-Dihydropyridine scaffold in medicinal chemistry, the story so far and perspectives (part 1): action in ion channels and GPCRs.
Ioan P; Carosati E; Micucci M; Cruciani G; Broccatelli F; Zhorov BS; Chiarini A; Budriesi R
Curr Med Chem; 2011; 18(32):4901-22. PubMed ID: 22050742
[TBL] [Abstract][Full Text] [Related]
17. Synthesis, study of 3D structures, and pharmacological activities of lipophilic nitroimidazolyl-1,4-dihydropyridines as calcium channel antagonist.
Miri R; Javidnia K; Sarkarzadeh H; Hemmateenejad B
Bioorg Med Chem; 2006 Jul; 14(14):4842-9. PubMed ID: 16603367
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of the inhibitory effect of dihydropyridines on N-type calcium channel by virtual three-dimensional pharmacophore modeling.
Ogihara T; Kano T; Kakinuma C
Arzneimittelforschung; 2009; 59(6):283-8. PubMed ID: 19634509
[TBL] [Abstract][Full Text] [Related]
19. 1,4-Dihydropyridine derivatives with T-type calcium channel blocking activity attenuate inflammatory and neuropathic pain.
Bladen C; Gadotti VM; Gündüz MG; Berger ND; Şimşek R; Şafak C; Zamponi GW
Pflugers Arch; 2015 Jun; 467(6):1237-47. PubMed ID: 24990197
[TBL] [Abstract][Full Text] [Related]
20. Antagonism of 4-substituted 1,4-dihydropyridine-3,5-dicarboxylates toward voltage-dependent L-type Ca2+ channels Ca V 1.3 and Ca V 1.2.
Chang CC; Cao S; Kang S; Kai L; Tian X; Pandey P; Dunne SF; Luan CH; Surmeier DJ; Silverman RB
Bioorg Med Chem; 2010 May; 18(9):3147-58. PubMed ID: 20382537
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
